Surf Therapeutics

Executive Summary

Surf Therapeutics is a preclinical-stage biotechnology company pioneering novel RNA-targeted medicines and delivery technologies for challenging neurological disorders. Founded in 2021 and based in Cambridge, MA, the company is developing proprietary platforms to deliver therapeutic oligonucleotides across the blood-brain barrier and into specific neuronal cells, addressing genetically defined neurological diseases with high unmet need. Despite being at an early stage with limited public data, Surf Therapeutics addresses a critical challenge in CNS drug development—effective delivery across the blood-brain barrier. The company's approach leverages oligonucleotide therapeutics, a modality that has gained significant traction in recent years with approved drugs for spinal muscular atrophy and Duchenne muscular dystrophy. Surf Therapeutics has the potential to unlock a new class of treatments for disorders such as Huntington's disease, ALS, and various forms of ataxia. However, as a private preclinical company, it faces substantial technical and financial risks, and the platform's differentiation and preclinical validation remain to be proven.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round70% success
• TBDPreclinical Proof-of-Concept Data Release40% success
• TBDLead Candidate IND Submission20% success